Literature DB >> 29527254

Cross-Sectional HIV Incidence Surveillance: A Benchmarking of Approaches for Estimating the 'Mean Duration of Recent Infection'.

Reshma Kassanjee1,2, Daniela De Angelis3, Marian Farah3, Debra Hanson4, Jan Phillipus Lourens Labuschagne2,5, Oliver Laeyendecker6,7,8, Stéphane Le Vu9,10, Brian Tom3, Rui Wang11,12, Alex Welte2.   

Abstract

The application of biomarkers for 'recent' infection in cross-sectional HIV incidence surveillance requires the estimation of critical biomarker characteristics. Various approaches have been employed for using longitudinal data to estimate the Mean Duration of Recent Infection (MDRI) - the average time in the 'recent' state. In this systematic benchmarking of MDRI estimation approaches, a simulation platform was used to measure accuracy and precision of over twenty approaches, in thirty scenarios capturing various study designs, subject behaviors and test dynamics that may be encountered in practice. Results highlight that assuming a single continuous sojourn in the 'recent' state can produce substantial bias. Simple interpolation provides useful MDRI estimates provided subjects are tested at regular intervals. Regression performs the best - while 'random effects' describe the subject-clustering in the data, regression models without random effects proved easy to implement, stable, and of similar accuracy in scenarios considered; robustness to parametric assumptions was improved by regressing 'recent'/'non-recent' classifications rather than continuous biomarker readings. All approaches were vulnerable to incorrect assumptions about subjects' (unobserved) infection times. Results provided show the relationships between MDRI estimation performance and the number of subjects, inter-visit intervals, missed visits, loss to follow-up, and aspects of biomarker signal and noise.

Entities:  

Keywords:  HIV; biomarkers for recent infection; cross-sectional incidence surveys; duration of recent infection; incidence estimation

Year:  2017        PMID: 29527254      PMCID: PMC5842819          DOI: 10.1515/scid-2016-0002.

Source DB:  PubMed          Journal:  Stat Commun Infect Dis


  32 in total

1.  Improved HIV-1 incidence estimates using the BED capture enzyme immunoassay.

Authors:  John W Hargrove; Jean H Humphrey; Kuda Mutasa; Bharat S Parekh; J Steve McDougal; Robert Ntozini; Henry Chidawanyika; Lawrence H Moulton; Brian Ward; Kusum Nathoo; Peter J Iliff; Ekkehard Kopp
Journal:  AIDS       Date:  2008-02-19       Impact factor: 4.177

2.  A new general biomarker-based incidence estimator.

Authors:  Reshma Kassanjee; Thomas A McWalter; Till Bärnighausen; Alex Welte
Journal:  Epidemiology       Date:  2012-09       Impact factor: 4.822

3.  Estimation of the distribution of infection times using longitudinal serological markers of HIV: implications for the estimation of HIV incidence.

Authors:  C Sommen; D Commenges; S Le Vu; L Meyer; A Alioum
Journal:  Biometrics       Date:  2010-08-23       Impact factor: 2.571

Review 4.  Modeling sequence evolution in acute HIV-1 infection.

Authors:  Ha Youn Lee; Elena E Giorgi; Brandon F Keele; Brian Gaschen; Gayathri S Athreya; Jesus F Salazar-Gonzalez; Kimmy T Pham; Paul A Goepfert; J Michael Kilby; Michael S Saag; Eric L Delwart; Michael P Busch; Beatrice H Hahn; George M Shaw; Bette T Korber; Tanmoy Bhattacharya; Alan S Perelson
Journal:  J Theor Biol       Date:  2009-08-04       Impact factor: 2.691

5.  HIV incidence determination in the United States: a multiassay approach.

Authors:  Oliver Laeyendecker; Ron Brookmeyer; Matthew M Cousins; Caroline E Mullis; Jacob Konikoff; Deborah Donnell; Connie Celum; Susan P Buchbinder; George R Seage; Gregory D Kirk; Shruti H Mehta; Jacquie Astemborski; Lisa P Jacobson; Joseph B Margolick; Joelle Brown; Thomas C Quinn; Susan H Eshleman
Journal:  J Infect Dis       Date:  2012-11-05       Impact factor: 5.226

6.  Augmented cross-sectional prevalence testing for estimating HIV incidence.

Authors:  Rui Wang; Stephen W Lagakos
Journal:  Biometrics       Date:  2010-09       Impact factor: 2.571

7.  Estimating the distribution of the window period for recent HIV infections: a comparison of statistical methods.

Authors:  Michael J Sweeting; Daniela De Angelis; John Parry; Barbara Suligoi
Journal:  Stat Med       Date:  2010-12-30       Impact factor: 2.373

8.  Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies.

Authors:  Yen T Duong; Maofeng Qiu; Anindya K De; Keisha Jackson; Trudy Dobbs; Andrea A Kim; John N Nkengasong; Bharat S Parekh
Journal:  PLoS One       Date:  2012-03-27       Impact factor: 3.240

9.  Recalibration of the limiting antigen avidity EIA to determine mean duration of recent infection in divergent HIV-1 subtypes.

Authors:  Yen T Duong; Reshma Kassanjee; Alex Welte; Meade Morgan; Anindya De; Trudy Dobbs; Erin Rottinghaus; John Nkengasong; Marcel E Curlin; Chonticha Kittinunvorakoon; Boonyos Raengsakulrach; Michael Martin; Kachit Choopanya; Suphak Vanichseni; Yan Jiang; Maofeng Qiu; Haiying Yu; Yan Hao; Neha Shah; Linh-Vi Le; Andrea A Kim; Tuan Anh Nguyen; William Ampofo; Bharat S Parekh
Journal:  PLoS One       Date:  2015-02-24       Impact factor: 3.240

10.  Evaluation of a multiplex assay for estimation of HIV-1 incidence.

Authors:  Kelly A Curtis; Debra L Hanson; M Susan Kennedy; S Michele Owen
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

View more
  2 in total

1.  Impact of Early Antiretroviral Treatment Initiation on Performance of Cross-Sectional Incidence Assays.

Authors:  Ethan Klock; George Mwinnya; Leigh Anne Eller; Reinaldo E Fernandez; Hannah Kibuuka; Sorachai Nitayaphan; Josphat Kosgei; Richard D Moore; Merlin Robb; Susan H Eshleman; Oliver Laeyendecker
Journal:  AIDS Res Hum Retroviruses       Date:  2020-05-27       Impact factor: 2.205

2.  Quantitative interpretation of Sedia LAg Assay test results after HIV diagnosis.

Authors:  Joseph B Sempa; Eduard Grebe; Alex Welte
Journal:  PLoS One       Date:  2022-07-28       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.